Early recovery of host-derived hematopoiesis in marrow transplant recipients conditioned with high-dose busulfan and cyclophosphamide.
Three marrow transplant recipients with hematologic malignancies (two AML, one myelodysplastic syndrome) experienced prolonged pancytopenia after allogeneic BMT following conditioning with non-TBI regimens containing high-dose busulfan and cyclophosphamide (Bu/CY), despite the use of G-CSF. Early recovery of host-derived hematopoiesis ensued. Although neutrophil counts in these patients exceeded 500 x 10(6)/l by day 30 after transplant, these cells were of host origin. This early recovery of host-derived hematopoiesis has been observed rarely among patients conditioned with TBI-based regimens. When patients conditioned with Bu/CY show delayed hematologic recovery, mixed chimerism should be considered even in the presence of normal neutrophil recovery.
Yamaguchi
M
M
Third Department of Medicine, Kanazawa University School of Medicine, Japan.
Nakao
S
S
Ueda
M
M
Takamatsu
H
H
Tamaru
Y
Y
Shiobara
S
S
Masauji
N
N
Matsue
K
K
Matsuda
T
T
D000293:Adolescent; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use*; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006410:Hematopoiesis; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D013997:Time Factors; D014916:Whole-Body Irradiation
D003520:Cyclophosphamide; D002066:Busulfan